Efficacy and Safety of Tenectaplase versus Streptokinase in Treating ST‐Elevation Myocardial Infarction Patients in Hong Kong: A Four‐Year Retrospective Review in Queen Elizabeth Hospital

Objective Data were lacking in comparing tenectaplase (TNK) and streptokinase (SK) in treating Chinese ST elevation myocardial infarction (STEMI) patients. We sought to compare these 2 types of thrombolytics in our locality. Methods We analysed 196 STEMI patients who received either TNK or SK in our hospital from 2007 to 2011. We compared the mortality and other outcomes of these 2 groups of patients. Results In‐hospital mortality has no significant difference between the TNK and the SK groups (8.9% vs 5.3%, p=0.322). Door‐to‐needle time was shorter in the TNK group (31±10 vs 25±7, p<0.001). Hypotension after drug administration was more common in the SK group than in the TNK group (21.1% vs. 3.0%, p<0.001). Conclusion TNK is at least as safe as SK in treating STEMI patients, with the advantage of shorter door‐to‐needle time and less frequent hypotensive effect. (Hong Kong j.emerg.med. 2013;20:359‐363)